SYNDEVRX INC
CAMBRIDGE, MA · Founded 2007 · CIK 0001455364 · Biotech · Private
Small molecule therapeutics targeting cancer metabolism and angiogenesis
syndevrx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $38M
- 8 Form D · Nov 2024
- 23 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 18 granted · 22 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200820102012201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $569,659 | |
| Private capital raised | Form D · SEC | $80,000 | |
| Private capital raised | Form D · SEC | $15,000 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $6,100,000 | |
| Private capital raised | Form D · SEC | $29,354,820 | |
| Private capital raised | Form D · SEC | $978,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2294 | Fortress Biotech, Inc. | — | $39M |
| 2295 | Tortugas Neuroscience | — | — |
| 2296 | FutureDerm Inc. | — | $468K |
| 2297 | SYNDEVRX INC | — | $38M |
| 2298 | Zya, Inc. | — | $37M |
| 2299 | Cyclacel Pharmaceuticals, Inc. | — | $36M |
| 2300 | Retrotope, Inc. | — | $32M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Bradley CarverDirector · Executive Officer
- Michael CliffordDirector
- Charles FlynnDirector
- Charlie FlynnDirector
- Richard LoveDirector
- David NeafusExecutive Officer
- John PetersenExecutive Officer
- John PetersonExecutive Officer
- Joanne SchindlerExecutive Officer
- James ShanahanDirector · Executive Officer
- Eric TookerDirector
- Jeffrey WellesDirector
Patents
- METAP2 Inhibitors And Methods Of Treating Obesityapplication
- Combinations Comprising METAP2 Inhibitors For The Treatment Of Cancerapplication
- Biomarkers Of METAP2 Inhibitors And Applications Thereofapplication
- Biomarkers Of METAP2 Inhibitors And Applications Thereofgranted
- Polymer-conjugated METAP2 Inhibitors, And Therapeutic Methods Of Use Thereofapplication
- Combinations Of METAP2 Inhibitors And CD4/6 Inhibitors For The Treatment Of Cancerapplication
- Polymer-conjugated METAP2 Inhibitors, And Therapeutic Methods Of Use Thereofapplication
- Biomarkers Of METAP2 Inhibitors And Applications Thereofgranted
- METAP2 Inhibitors And Methods Of Treating Obesityapplication
- Treatment For Tumors Driven By Metabolic Dysfuctionapplication
- METAP2 Inhibitors And Methods Of Treating Obesitygranted
- Treatment For Tumors Driven By Metabolic Dysfunctiongranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.